# Blinatumomab Trimer Formation: Insights From A Mechanistic PKPD Model Into The Implications For Switching From Infusion To Subcutaneous Dosing Regimen 

Georgi I. Kapitanov ${ }^{1}$; Sarah A. Head $^{1}$; David Flowers ${ }^{1}$; Joshua F. Apgar ${ }^{1}$; Joshuaine Grant ${ }^{1}$

${ }^{1}$ Applied BioMath, Concord, MA, USA

Corresponding author: Georgi I. Kapitanov, georgi.kapitanov@appliedbiopmath.com
561 Virginia Road, Suite 220
Concord, MA 01742
Tel: (617) 914-8855

Key words: T-cell engager, QSP, blinatumomab, bispecific, mathematical model, subcutaneous administration

CONFLICT OF INTEREST
The authors declared no competing interests for this work.

## FUNDING

No funding to declare


#### Abstract

Blinatumomab is a bispecific T-cell engager (BiTE) that binds to CD3 on T cells and CD19 on B cells. It has been approved for use in B-cell acute lymphoblastic leukemia (B-ALL) with a regimen that requires continuous infusion (cIV) for four weeks per treatment cycle. It is currently in clinical trials for Non-Hodgkin lymphoma (NHL) with cIV administration. Recently, there have been studies investigating dose-response after subcutaneous (SC) dosing in B-ALL and in NHL to determine whether this more convenient method of delivery would have a similar efficacy/safety profile as continuous infusion. We constructed mechanistic PKPD models of blinatumomab activity in B-ALL and NHL patients, investigating the amount of CD3:blinatumomab:CD19 trimers the drug forms at different dosing administrations and regimens.


The modeling and analysis demonstrate that the explored SC doses in B-ALL and NHL achieve similar trimer numbers as the cIV doses in those indications. We further simulated various subcutaneous dosing regimens, and identified conditions where trimer formation dynamics are similar between constant infusion and subcutaneous dosing. Based on the model results, subcutaneous dosing is a viable and convenient strategy for blinatumomab and is projected to result in similar trimer numbers as constant infusion.

## Introduction

Current treatments for cancers with B-cell derived malignancy, such as Non-Hodgkin lymphoma, show improved outcomes for some patients, but there are still many patients experiencing relapse, refractory disease or resistance. Blinatumomab (BLINCYTO ${ }^{\mathrm{TM}}$, Amgen, Thousand Oaks, CA) is a bispecific T-cell engager (BiTE) that binds to CD3 on T cells and CD19 on B cells, resulting in T-cell mediated lysis of the B-cells. The lysis is mediated in part by the trimeric complex (trimer) that is formed through the binding of blinatumomab to both CD3 and CD19. The trimer promotes the formation of an immunological synapse between the Tand B-cells, leading to T-cell activation, T-cell proliferation and B-cell lysis. Blinatumomab has been approved for use by the United States Food and Drug Administration (FDA) for adult Philadelphia chromosome negative relapsed or refractory ( $\mathrm{R} / \mathrm{R}$ ) B cell progenitor acute lymphoblastic leukemia (B-ALL) in 2014, and for R/R Philadelphia chromosome-positive BALL in 2017. Blinatumomab was also approved for the treatment of minimal residual disease (MRD) in B-ALL patients in 2018.

The half-life of blinatumomab is only 2-3 hours, requiring it to be administered through continuous intravenous infusion (cIV) for four weeks per treatment cycle ${ }^{1-4}$. It is currently in clinical trials for Non-Hodgkin lymphoma (NHL) with cIV administration ${ }^{5}$. Recently, there have been studies investigating dose-response after subcutaneous (SC) dosing (in B-ALL ${ }^{6}$ and in
$\mathrm{NHL}^{7}$ ) to evaluate whether this more convenient method of delivery would have a similar efficacy/safety profile as continuous infusion.

While trimer formation is challenging to measure experimentally, there are several examples where mathematical modeling and simulation have assisted in understanding the complexities of TCE molecules and informing quantitative decision making ${ }^{8-14}$. In this work, literature and available clinical data are used to develop a PKPD model of blinatumomab in B-ALL and NHL. The model was then used to simulate blinatumomab PK and predict trimer formation in the bone marrow in the case of B-ALL or in the tumor environment in NHL patients, both after continuous infusion and subcutaneous administration. The predicted efficacious doses were then compared to those currently being evaluated in the clinic. The model readout used for this comparison is the trimers formed between T cells and cancer cells, since it has been hypothesized that this is the primary driver of pharmacological effect ${ }^{8}$.

## Methods

## Model Description and Parameterization

We constructed mechanistic PKPD models of B-ALL and NHL that describe blinatumomab PK in circulation, exposure at the site of action (the bone marrow for B-ALL and solid tumor for NHL) and peripheral tissue, engagement with CD3 on T cells and CD19 on normal and malignant B cells, and the amount of trimers the TCE forms at different dosing administrations and regimens. The different components of the model are described below and the Model diagram is presented in Figure 1.

## Drug administration, distribution, and elimination

Blinatumomab is administered either through continuous intravenous (cIV) infusion or subcutaneously. When cIV administration is applied, blinatumomab enters the central compartment at the clinical reported infusion rate. When administered subcutaneously, blinatumomab is absorbed from a depot compartment, into the central compartment with a rate constant (kabs), determined by its half-life (Thalf_abs_day), using an applied bioavailability (fbio). The drug is assumed to eliminate with the same rate constant (kel) in all compartments. Bidirectional distribution from the central to peripheral or central to tumor compartments occurs using blinatumomab distribution parameters Pdist, which is the partition coefficient between plasma and the relevant tissue, and Tdist, which is the half-life of distribution to that compartment.

The first order drug distribution parameters (k12 and k21, k13 and k31) are calculated from Pdist (partition coefficient between plasma and tissue/tumor) and Tdist (half-life of distribution) through the following algebraic relationship:

$$
\begin{aligned}
& \mathrm{k}_{\mathrm{ij}}=\log (2) / \text { Tdist_ij } * \text { Pdist_ij } /\left(\text { Pdist_ij }+\mathrm{V}_{\mathrm{i}} / \mathrm{V}_{\mathrm{j}}\right) \\
& \mathrm{k}_{\mathrm{ji}}=\log (2) / \text { Tdist_ij } /\left(1+\text { Pdist_ij } \text { * } \mathrm{V}_{\mathrm{j}} / \mathrm{V}_{\mathrm{i}}\right)
\end{aligned}
$$

where $i$ and $j$ are the compartment indexes -1 for central, 2 for peripheral, 3 for the site of action (tumor or bone marrow). It is assumed that there is no direct distribution between the peripheral compartment and the site of action.

## CD19 and CD3 protein dynamics

CD19 and CD3 internalization (equivalent to degradation) are included in the model. Synthesis is a zeroth order process, parameterized to ensure constant total (free and bound) protein levels for both targets in each compartment. Internalization is modeled as a single first-order process. The blinatumomab:target complex is assumed to internalize at the rate of the target, while the trimer complex can internalize with either target, releasing the other target in the process to maintain the constant total target level. For example, internalization of the CD3:blinatumomab:CD19 trimer complex through internalization of CD3 results in degradation of CD3 and blinatumomab but returns free CD19. Cellular movement between compartments is not modeled, hence there is no distribution of the targets between compartments.

The initial steady state concentration of CD19 and CD3 was informed from literature estimates of numbers of CD19+ or CD3+ cells, measured receptor expression per cell for both cancer cells and normal B cells, and physiological parameters such as compartment volumes. The cancer cell numbers were determined from clinical data from NHL and B-ALL patients, either by direct cell counts or inferred through the data. These values were selected to represent nominal NHL and BALL patients with moderate disease progression. Off-tumor cell counts were obtained from standard values in the literature. For CD19 receptor densities, a representative value was chosen from quantification of receptors per cell that was reported in the literature. The turnover rates of both CD3 and CD19 were obtained from the literature. For all parameter values and references see Tables $\underline{\mathrm{S} 1}$ and $\underline{\mathrm{S} 2}$.

## Binding of blinatumomab to CD3 and CD19, cross-linking

Blinatumomab can bind to either CD3 or CD19 on T cells and B cells, respectively, after which a second binding step, in which blinatumomab binds the target on the other cell type, is modeled. The second binding (cross-linking) creates a CD3:blinatumomab:CD19 trimeric molecule ("trimer"). The one-step binding of blinatumomab to either target is modeled through a traditional concentration-dependent reversible binding step. The second binding step results in trimer formation, is modeled as occurring on the cell surface, and is dependent on the density
(molecule per cell surface area) of the blinatumomab:CD3 complex on T cells and the CD19 density on B cells or blinatumomab:CD19 complex on B cells, and the CD3 density on T cells. A detailed description and discussion of the second binding step as density-dependent, and the advantages of this approach in modeling T-cell engagers, can be read in Flowers, D. et al. ${ }^{15}$.

All binding reactions are reversible and described with association and dissociation rate constants. The association rate parameter (kon) was assumed to be the same for all binding interactions, based on reported protein-protein interaction kinetics ${ }^{16}$. Blinatumomab's KDs to CD3 and CD19 are 260 nM and 1.49 nM , respectively, and were taken from the literature ${ }^{17}$.

The cross-linking association rate, kon2, was assumed to be $1000 \mathrm{dm}^{2} / \mathrm{nmol} / \mathrm{s}$, a typical value based on unpublished internal research experience. The effect of this value on the final dose projections is explored through sensitivity analysis (see Results).

## B cell depletion

In addition to the basal turnover of CD19 on normal B cells, the models include explicit normal B cell killing. Including B-cell depletion is done to capture potential effects of TMDD. Cancer cells, for the purpose of the model, are not killed. The killing function is trimer-dependent and defines a rate at which B cells are removed from the compartment in which they reside. The same removal rate is applied to all CD19-dependent molecules on normal B cells (free CD19, blinatumomab:CD19 complex, and trimers) and it is assumed that the CD19 associated with that complex is removed from the system, while other species are dissociated from that complex. For example, a blinatumomab:CD19 complex to which the killing rate is applied returns unboundblinatumomab, while a trimer to which the killing rate is applied will return a blinatumomab:CD3 complex.

The function that defines B-cell depletion, $f \_k i l l$, has the form:

```
f_kill = k_kill * Avg TpT / (Avg TpT + kill_EC50)
```

where $k$ kill is the maximum killing velocity, Avg TpT is the running average Trimers per T cell ( TpT ) in the relevant model compartment, and kill_EC50 is the Avg TpT that results in half-max depletion. kill_EC50 was fixed at 100, meaning that an Avg Tpt of 100 will result in half-max depletion of normal B cells; the effect of this value on the final dose projections is explored through sensitivity analysis (see Results). k_kill was determined by a literature search on the effect of blinatumomab on B-cell depletion. Depletion half-life estimates from the literature ranged from less than 1 h to up to $6 \mathrm{~h}^{5,18-20}$. Based on these observations, the maximum killing half-life was fixed at 1 h , which resulted in $\mathrm{k} \_$kill $=\log (2) / 1 \mathrm{~h}=2 \mathrm{e}-41 / \mathrm{s}$.

The parameters, their descriptions, along with the assumptions and appropriate references are described in detail in Table S1 for B-ALL and Table $\underline{\mathrm{S} 2}$ for NHL.

## Analysis Workflow

All blinatumomab parameters besides the absorption half-life after SC dosing (Thalf_abs_day) were fixed to literature values (See Table S1 and Table S2). The absorption half-life was estimated from PK data from a blinatumomab NHL study with SC administration ${ }^{7}$. The data used for model calibration and verification were digitized from published plots(Rossi et al. 2021; Sánchez et al. 2021). The predicted PK was then compared against reported clinical steady-state concentration levels achieved after continuous infusion of blinatumomab ${ }^{5}$, as well as clinical PK data from B-ALL patients after SC administration ${ }^{6}$. The cIV NHL study doses were reported in $\mathrm{ug} / \mathrm{m}^{2} /$ day but in subsequent NHL studies, blinatumomab was dosed in ug. The model input was in ug doses only, which were adjusted accordingly for the cIV study for an assumed typical 70 $\mathrm{kg}, 175 \mathrm{~cm}$ patient.

To compare cIV and SC dosing, a metric equating average trimer per T cell (TpT) for trimers connecting cancer and T cells at the site of action (tumor for NHL and bone marrow for B-ALL) was used. The average TpT was calculated by dividing the AUC of trimers per T cell by the time point of interest. Average trimers per T cell at day 28 at cIV clinical doses of interest ( $28 \mathrm{ug} / \mathrm{day}$ for B-ALL and $60 \mathrm{ug} / \mathrm{m}^{2} /$ day for NHL) were projected by the model. A scan of doses with SC administration to match the number of trimers achieved at the cIV doses was performed with QD and Q2D regimens, in 5 ug increments.

The models were implemented using the Applied BioMath QSP Notebook v2022.6.4 and the text file of the model reactions for the B-ALL model is shared in Supplemental Materials 3.

## Results

The blinatumomab absorption half-life after SC administration was estimated at 0.527 days. The simulated PK profiles vs data in the NHL clinical trial can be seen in Figure 2 and the goodness-of-fit projected vs observed values can be seen in Figure S1.

Next, steady-state concentrations after cIV administration in NHL and B-ALL patients were simulated and compared to reported Css values. The observed vs predicted values can be seen in Tables $\underline{1}$ and 2 .

Clinical trials with SC dosing in B-ALL were also conducted and the model simulations of PK were compared to the observed concentrations. Simulations of the approved cIV doses of 9 $\mathrm{ug} /$ day and $28 \mathrm{ug} /$ day were also performed for comparison. The results can be seen in Figure 3.

With general agreement between projected and observed PK , simulations were run to compare the average trimer per T cell ( TpT ) formed between T cells and cancer cells at the site of action using the tested clinical doses. For NHL, the results can be seen in Figure 4 and for B-ALL in Figure 5. Different doses are in different colors, solid lines indicate SC administration, while dashed lines indicate cIV administration. Overall, predicted TpT at the clinical SC doses align with the predicted TpT at the higher infusion doses. Table 3 and Table $\underline{4}$ contain comparisons between average TpT at the site of action for administered doses for NHL and B-ALL, respectively.

To compare the TpT for cIV regimens against potential SC regimens, a range of SC administered doses were simulated and the results at day 28 , the end of one typical cycle of blinatumomab, were compared to the day 28 steady state results after cIV administration. For B-ALL, $28 \mathrm{ug} / \mathrm{day}$ cIV was predicted to achieve 18.9 average TpT by day 28. With SC administration, doses of 115 ug QD and 225 ug Q2D were projected to achieve the same amount of trimers (See Table 5). Comparison of the number of trimers achieved with the three doses can be seen in Figure 6. For NHL, the dose of $60 \mathrm{ug} / \mathrm{m}^{2} /$ day cIV, equivalent to $112 \mathrm{ug} /$ day cIV as administered in subsequent studies, was chosen as the dose for which to find an equivalent dose with SC administration. 112 $\mathrm{ug} /$ day is projected to achieve 8.9 TpT in the tumor and the same amount of trimers are achieved with 450 ug QD and 890 ug Q2D. Comparison of the number of trimers achieved with the three doses can be seen in Figure 7. Table 5 contains the projected average site-of-action number of trimers for each dose and indication.

A one-at-a-time sensitivity analysis was performed to explore the effect of fold-change of each model parameter on the average TpT at the site of action at day 28 . For each indication, two fixed doses were explored - the cIV dose used to evaluate SC equivalence ( $112 \mathrm{ug} / \mathrm{day}$ for NHL and $28 \mathrm{ug} /$ day for B-ALL) and the equivalent SC QD doses from the result above ( 450 ug for NHL and 115 ug for B-ALL). The fold-change for each parameter varied between 2, 3, and 10, depending on the parameter type and the level of uncertainty in parameter estimation. For example, the central volume was only varied two-fold in either direction, since the plasma volume is not expected to vary substantially for the typical individual. In contrast, the crosslinking on-rate constant was varied ten-fold since the value has not been experimentally determined and in the case that it had been measured, variations between in vitro and in vivo measurements could be expected (hence why the affinities are also varied by ten-fold). Figures
 parameters were ranked based on the absolute difference in average TpT resulting from simulations with the top and the bottom values of the parameter. Only the top 15 most sensitive parameters are pictured. The most sensitive parameters are different for the two indications. For B-ALL, the most sensitive parameters are the on-rate constants, the affinity to CD3, the number of CD3 molecules per T cell and the elimination half-life. For NHL, the most sensitive parameters are the number of T cells, the distribution of blinatumomab to the tumor, the tumor volume, and the internalization rate of CD19.

When comparing the results between the cIV and the SC doses (Figures $\underline{S} 2$ vs $\underline{S 3}$ for NHL and $\underline{\mathrm{S} 4}$ vs $\underline{\mathrm{S} 5}$ for B-ALL), besides bioavailability, which has no effect on cIV simulations, the order of the sensitive parameters and the magnitude by which they change the TpT projections is almost identical within each indication. This indicates that even if parameters change, a similar SC dose to what is currently projected will achieve the equivalent TpT as its cIV counterpart, making the current dose-equivalence results insensitive to parameter fluctuations within the folds explored.

## Discussion

The TCE model constructed here was used to bridge the currently used cIV and the explored SC dosing regimens for blinatumomab by exploring the effect of each on a model-based metric of effect - average trimers per T cell at the site of action. The two SC dosing regimens that were used were QD and Q2D. Based on the modeling results, for B-ALL, in order to achieve the same TpT as $28 \mathrm{ug} /$ day cIV, 115 ug SC QD or 225 ug SC Q2D would be required. For NHL, in order to achieve the same TpT as $112 \mathrm{ug} / \mathrm{day}$ cIV, 450 ug SC QD or 890 ug SC Q2D would be required. These clinical doses align well with what has already been explored in the clinic, which validates the modeling results. For B-ALL, 120 ug QD, followed by 250 ug TIW has been explored in a clinical study ${ }^{6}$. For NHL, a 450 ug SC QD regimen was also a part of a clinical study ${ }^{7}$. Furthermore, the equivalent SC dose projections are insensitive to parameter fluctuations as explored by sensitivity analysis, which increases the robustness of the dose projections.

The model does not address the full complexity of either disease and the full effect of drug intervention on patients. Cellular dynamics, beyond B-cell depletion, which was incorporated for capturing the TMDD dynamics more accurately, have not been explored. T-cell activation, proliferation, and site-of-action infiltration, along with cancer cell death have not been explored they could be an important component of both effective dose predictions and bridging the cIV to SC dosing. The effect of blinatumomab on cytokine release syndrome (CRS) and other adverse events was also not modeled, while those considerations are crucial when making decisions on changes in administration. Furthermore, in the clinic, in order to mitigate the effect of CRS on patients, a step-wise dosing approach is utilized - the patients are not dosed at the final efficacious dose but a lower dose is initially used to "prime" the immune system ${ }^{23,24}$. For example, in B-ALL, the first month-long cycle with blinatumomab is at $9 \mathrm{ug} / \mathrm{day}$ cIV, which is then increased to $28 \mathrm{ug} /$ day in subsequent cycles ${ }^{1}$. However, to our knowledge, comprehensive dynamics of CRS and proliferation data are not available in the literature for blinatumomab and particularly for the SC dosing regimens. Hence, while the model can easily be expanded to incorporate these dynamics, they are beyond the scope of the current study.

It is unclear whether average trimer per T cell is the correct metric to explore for an effective dose, considering the speed of B-cell depletion, the process of activating T cells and subsequent
death of target cells appear to be relatively quick when compared to the length of treatment cycle (a few hours vs a month). Therefore, a maximum trimer metric may be a reasonable approach, which would lead to projecting lower effective doses with SC administration when compared to cIV doses (not shown here). However, given cancer cell resilience and variable patient responses, a trough trimer metric is not out of the question, which would lead to higher projected effective doses with SC administration. More blinatumomab clinical data with SC dosing is needed to guide the appropriate metric for determining safe and effective doses.

The sensitivity analysis results for the model projections for B-ALL and NHL revealed that when access to the site of action is limited, as is the case with NHL in the model, overcoming this limitation and increasing distribution is more important than the act of forming trimers. However, when the site of action provides easy access, as is the case with bone marrow in BALL, the actual binding and forming trimers is more sensitive.

Furthermore, the model predicts fewer trimers being formed in the NHL site of action than BALL. This prediction aligns well with the higher blinatumomab doses explored in NHL vs BALL in the clinic. While distribution is likely not the only factor that makes NHL more challenging for blinatumomab than B-ALL, the model assumption that the drug concentration in the tumor is lower than that in the bone marrow and hence leads to fewer trimers formed in the tumor versus the bone marrow, aligns with clinical observations.

Further work exploring the model results and comparing safety profiles between cIV and SC dosing is necessary for a robust understanding for optimal dosing regimens. Those explorations and predictions can be achieved with the current model but more data are needed to validate the model predictions.

## Study Highlights

Articles should include a Study Highlights section after the Discussion in the manuscript text. The highlights section should include and answer each of the questions below. The entire section, not including the questions, should be under 150 words.

- What is the current knowledge on the topic?

To our knowledge no external publication attempt has been made to bridge the cIV to SC dosing for blinatumomab, hence the method for bridging has not been explored in the literature.

- What question did this study address?

The study showcases a model that predicts the doses with SC administration that can achieve the same formation of CD3:blinatumomab:CD19 molecules, hypothesized to be directly related to efficacy, as the currently approved cIV administration for blinatumomab.

- What does this study add to our knowledge?

The study suggests which SC doses should be explored in the clinic for blinatumomab. Given that the SC administration is novel for this molecule, the model's predictions can be applied to future clinical studies.

- How might this change clinical pharmacology or translational science?

T-cell engagers are challenging molecules to model and predict safe and efficacious doses in the clinic. The study presents a potential method for bridging IV to SC dosing regimens for TCEs.

Acknowledgements: The authors would like to thank Victor Chang for his contribution to the study of T-cell engagers at Applied BioMath.

Author Contributions: GK, SH, JA, DF, and JG wrote the manuscript; GK and JG designed the research; GK, SH, and DF performed the research; GK and SH analyzed the data.

## References

1. BLINCYTO (blinatumomab) [package insert], Thousand Oaks, CA, Amgen Inc., 2022.
2. Goebeler, M.-E. et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. J. Clin. Oncol. 34, 1104-1111 (2016).
3. Viardot, A. et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127, 1410-1416 (2016).
4. Katz, D. A. et al. Open-Label, Phase 2 Study of Blinatumomab after First-Line RituximabChemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma. Blood

134, 4077 (2019).
5. Hijazi, Y. et al. Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. Curr. Clin. Pharmacol. 13, 55-64 (2018).
6. Sánchez, P. M. et al. Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL). Blood 138, 2303 (2021).
7. Rossi, G. et al. A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL). Blood 138, 2436 (2021).
8. Betts, A. \& van der Graaf, P. H. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin. Pharmacol. Ther. (2020) doi:10.1002/cpt. 1961 .
9. Li, L., Gardner, I. \& Gill, K. Modeling the binding kinetics of bispecific antibodies under the framework of a minimal human PBPK model. AAPS NBC Poster Preprint at https://www.certara.com/poster/modeling-the-binding-kinetics-of-bispecific-antibodies-under-the-framework-of-a-minimal-human-pbpk-model-2/ (2014).
10. Schropp, J., Khot, A., Shah, D. K. \& Koch, G. Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy. CPT Pharmacometrics Syst Pharmacol 8, 177-187 (2019).
11. Yoneyama, T., Kim, M.-S., Piatkov, K., Wang, H. \& Zhu, A. Z. X. Leveraging a physiologicallybased quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma. PLoS Comput. Biol. 18, e1009715 (2022).
12. Campagne, O. et al. Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity. Clin. Cancer Res. 24, 2631-2641 (2018).
13. Ma, H. et al. A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid

Tumor. AAPS J. 22, 85 (2020).
14. Jiang, X. et al. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. MAbs 10, 876-889 (2018).
15. Flowers, D. et al. A next generation mathematical model for the in vitro to clinical translation of Tcell engagers. J. Pharmacokinet. Pharmacodyn. 50, 215-227 (2023).
16. Schlosshauer, M. \& Baker, D. Realistic protein-protein association rates from a simple diffusional model neglecting long-range interactions, free energy barriers, and landscape ruggedness. Protein Sci. 13, 1660-1669 (2004).
17. Dreier, T. et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100, 690-697 (2002).
18. Nägele, V. et al. Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab. Exp. Hematol. 100, 32-36 (2021).
19. Klinger, M. et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226-6233 (2012).
20. Zhu, M. et al. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin. Pharmacokinet. 55, 1271-1288 (2016).
21. Kuchimanchi, M., Zhu, M., Clements, J. D. \& Doshi, S. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy. Br. J. Clin. Pharmacol. 85, 807-817 (2019).
22. Clements, J. D., Zhu, M., Kuchimanchi, M., Terminello, B. \& Doshi, S. Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological

Malignancies. Clin. Pharmacokinet. 59, 463-474 (2020).
23. Nägele, V. et al. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp. Hematol. Oncol. 6, 14 (2017).
24. Mau-Sørensen, M. et al. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother. Pharmacol. 75, 1065-1073 (2015).

## Figure Legends

Figure 1. Blinatumomab model diagram. The model includes central, peripheral, and a site of action (bone marrow in B-ALL and tumor in NHL) compartments. CD3 is expressed on T cells, CD19 is expressed on both cancer and normal B cells. Blinatumomab can bind to both receptors on each cell with a kon on-rate and cross-link and form trimers with a kon2 on-rate. The drug can distribute between the central compartment and the other compartments and is eliminated in each compartment. After continuous infusion, blinatumomab enters the central compartment directly. After subcutaneous administration, blinatumomab is absorbed into the central compartment from a depot compartment. Figure created with BioRender.com.

Figure 2. Blinatumomab PK calibration to NHL SC study ${ }^{7}$. All parameters besides the absorption half-life were taken from the literature.

Figure 3. Blinatumomab model simulations vs observed B-ALL SC PK data ${ }^{6}$. The model captures the 40 ug QD followed by 250 ug data well. The PK profile of the cohort with 120 ug QD starting dose could not be captured, since the reported responses were not dose-proportional to the lower dose cohort data. The 9 ug cIV and 28 ug cIV profiles were simulated for illustrative and comparison purposes.

Figure 4. Blinatumomab NHL average TpT projections in the tumor with cIV and SC dosing regimens. The values shown are running averages - TpT AUC divided by the time point.

Figure 5. Blinatumomab B-ALL average TpT projections in the tumor with cIV and SC dosing regimens. The values shown running averages - TpT AUC divided by the time point.

Figure 6. Blinatumomab simulated Avg TpT in the bone marrow for predicted effective dose with QD or Q2D SC dosing for 28 days in B-ALL. The doses are picked so that the Avg TpT matches 28 ug/day cIV dose.

Figure 7. Blinatumomab simulated Avg TpT in the tumor for predicted effective dose with QD or Q2D SC dosing for 28 days in NHL. The doses are picked so that the Avg TpT matches 112 ug/day cIV dose.

## Supplementary Information Titles

Table S1: B-ALL Model parameters

Table S2: NHL Model parameters

Predicted vs Observed


Figure S1. Observed vs Predicted plot for the calibration of the model to NHL PK data.


Figure S2. Results from sensitivity analysis with SC dosing in NHL patients. The dosing schedule was fixed at 450 ug SC QD. The parameters were varied one at a time by several fold, as indicated in the legend, and the average TpT at day 28 was reported. The parameters are in rank order based on the highest absolute difference in the results between the top and bottom parameter value. Only the top fifteen values are shown. A description of the parameters and their nominal values are in Table S2.


Figure S3. Results from sensitivity analysis with cIV dosing in NHL. The dosing schedule was fixed at $112 \mathrm{ug} /$ day. The parameters were varied one at a time by several fold, as indicated in the legend, and the average TpT at day 28 was recorded. The parameters are in rank order based on the highest absolute difference in the results between the top and bottom parameter value. Only the top fifteen values are shown. A description of the parameters and their nominal values are in Table S2.


Figure S4. Results from sensitivity analysis with SC dosing in B-ALL. The dosing schedule was fixed at 115 ug SC QD. The parameters were varied one at a time by several fold, as indicated in the legend, and the average TpT at day 28 was recorded. The parameters are in rank order based on the highest absolute difference in the results between the top and bottom parameter value.
Only the top fifteen values are shown. A description of the parameters and their nominal values are in Table S1.


Figure S5. Results from sensitivity analysis with cIV dosing in B-ALL. The dosing schedule was fixed at $28 \mathrm{ug} / \mathrm{day}$. The parameters were varied one at a time by several fold, as indicated in the legend, and the average TpT at day 28 was recorded. The parameters are in rank order based on the highest absolute difference in the results between the top and bottom parameter value. Only the top fifteen values are shown. A description of the parameters and their nominal values are in Table S1.

## Supplemental Material 3: Model reaction file. Parameters are taken from Tables S1 and

 S2.```
### In vivo three compartment human model - TCE
### Targets are CD19 and CD3
### This is a model for simulating human efficacious dose in Acute Lymphocytic Leukemia (B-cell)
### A lot of the parameters are place holders and will be assigned with a table
%% ReactionModel@1
initialization = SteadyState(time_scale = 86400:s)
time_unit = s
default_state_unit = nmol
% components
#####################################################################################
##
# Parameters
# Available units:
# time_unit_names = {"fs", "ps", "ns", "us", "ms", "s", "min", "hr", "d", "w"}
# length_unit_names = {"fm", "pm", "nm", "um", "mm", "dm", "m"}
# mass_unit_names = {"fg", "pg", "ng", "ug", "mg", "g", "kg"}
# volume_unit_names = {"fL", "pL", "nL", "uL", "mL", "dL", "L"}
# amount_unit_names = {"fmol", "pmol", "nmol", "umol", "mmol", "mol"}
# concentration_unit_names = {"fM", "pM", "nM", "uM", "mM", "M"}
# molecular_mass_unit_names = {"Da", "kDa", "MDa"}
# unitless = {"1"}
# Parameters defining initial conditions - mouse
volume_central:L := 3 #ABM standard PK parameters
volume_peripheral:L := 11.11 #ABM standard PK parameters
volume_bone_marrow:L := 1.89 # Shah & Betts
area_per_Tcell_um2:(um^2) :=160
# The model incorporates both normal B-cells and Cancer B-cells (Rtarcell)
area_per_Bcell_um2:(um^2) := 145
area_per_Rtarcell_um2:(um^2) :=700
CD3_per_cell := 5.7e4 # ABM standard parameters
```

```
CD19_per_Bcell := 15e3 # ABM standard parameters
CD19_per_Tarcell := 7.5e3 # ABM standard parameters
# Parameters defining rates
# binding
kon_Ab_CD3:(1/nM/s) := 0.001
kon_Ab_CD19:(1/nM/s) := 0.001
kD_CD3_nM:nM := 10
kD_CD19_nM:nM :=0.01
kon2:(dm^2/nmol/s) := 100 # avid binding kon
# bispecific PK
Thalf_el_day:d := 17 #ABM standard PK parameters
Pdist12 := 0.19 #ABM standard PK parameters
Pdist13 := 0.9 # Distribution to BM
Tdist12_hr:hr := 34 #ABM standard PK parameters
Tdist13_hr:hr := 6 # Distribution to BM
Thalf_abs_day:d := 2.7 #ABM standard PK parameters
fbio := 0.625 #ABM standard PK parameters
# turnover
Thalf_CD3_hr:hr := 19
Thalf_CD19_hr:hr := 12
# Parameters for dosing drug
BW_kg:kg := 70
mw:(g/mol) := 65000
interval:d := 7
dose:(mg/kg) := 1e-3
dose_count := 21
k_kill:(1/s) := 1e-6
kill_EC50:1 := 100
# Assignments
# Conversion factors (those with just values could have been defined as parameters)
mL_per_L:(mL/L) = 1e3
mg_per_g:(mg/g) = 1e3
ug_per_g:(ug/g) = 1e6
nmol_per_mol:(nmol/mol) = 1e9
um_per_dm:(um/dm) = 1e5
SECONDS_PER_MINUTE:(s/min) = 60:(s/min)
SECONDS_PER_HOUR:(s/hr) = SECONDS_PER_MINUTE * 60:(min/hr)
SECONDS_PER_DAY:(s/d) = SECONDS_PER_HOUR * 24:(hr/d)
N_AV:(1/mol) = 6.022e23
NUM_PER_NMOL:(1/nmol) = N_AV / nmol_per_mol
```

```
### macroparameter-to-microparameter conversions ###
# PK
ugml_per_nM:((ug/mL)/(nmol/L)) = mw * ug_per_g / mL_per_L / nmol_per_mol
Thalf_Ab_CD3 = Thalf_CD3_hr
Thalf_Ab_CD19 = Thalf_CD19_hr
kabs = log(2) / (Thalf_abs_day * SECONDS_PER_DAY)
kel_Ab = log(2) / (Thalf_el_day * SECONDS_PER_DAY)
# Transport parameters
# peripheral
Q12 = log(2) / (Tdist12_hr * SECONDS_PER_HOUR)
k12 = Q12 * Pdist12 / (Pdist12 + volume_central / volume_peripheral)
k21 = Q12 / (1 + Pdist12 * volume_peripheral / volume_central)
# Bone marrow
Q13 = log(2) / (Tdist13_hr * SECONDS_PER_HOUR)
k13 = Q13 * Pdist13 / (Pdist13 + volume_central / volume_bone_marrow)
k31 = Q13 / (1 + Pdist13 * volume_bone_marrow / volume_central)
# Binding
koff_Ab_CD3 = kD_CD3_nM * kon_Ab_CD3
koff_Ab_CD19 = kD_CD19_nM * kon_Ab_CD19
kon2_Ab_CD3 = kon2
kon2_Ab_CD19 = kon2_Ab_CD3 * kon_Ab_CD19 / kon_Ab_CD3
# Internalization
kint_CD3 = log(2) / (Thalf_CD3_hr * SECONDS_PER_HOUR)
kint_CD19 = log(2) / (Thalf_CD19_hr * SECONDS_PER_HOUR)
kint_Ab_CD3 = log(2) / (Thalf_Ab_CD3 * SECONDS_PER_HOUR)
kint_Ab_CD19 = log(2) / (Thalf_Ab_CD19 * SECONDS_PER_HOUR)
# Defining initial state values
# Cell numbers
Tcells_c_number_0:1 := 2.3e9 # Lit ref
Tcells_p_number_0:1 := 9.14e10 # Lit ref
Tcells_bm_number_0:1 := 6.52e9 # Lit ref, assumed 20% of normal
Bcells_c_number_0:1 := 5.85e8 # Lit ref
Bcells_p_number_0:1 := 7.06e9 # Lit ref
Bcells_bm_number_0:1 := 1.7e9 # Lit Ref, assumed 20% of normal
Rtarcells_c_number_0:1 := 7e8 # Lit ref
Rtarcells_p_number_0:1 := 100 # Assumed
Rtarcells_bm_number_0:1 := 5.27e11 # Lit ref
CD3_c_0 = CD3_per_cell*Tcells_c_number_0 / N_AV * nmol_per_mol
CD3_p_0 = CD3_per_cell*Tcells_p_number_0 / N_AV * nmol_per_mol
CD3_bm_0 = CD3_per_cell*Tcells_bm_number_0 / N_AV * nmol_per_mol
```

```
B_cell_CD19_c_0 = CD19_per_Bcell*Bcells_c_number_0 / N_AV * nmol_per_mol
B_cell_CD19_p_0 = CD19_per_Bcell*Bcells_p_number_0 / N_AV * nmol_per_mol
B_cell_CD19_bm_0 = CD19_per_Bcell*Bcells_bm_number_0 / N_AV * nmol_per_mol
Tar_cell_CD19_c_0 = CD19_per_Tarcell*Rtarcells_c_number_0 / N_AV * nmol_per_mol
Tar_cell_CD19_p_0 = CD19_per_Tarcell*Rtarcells_p_number_0 / N_AV * nmol_per_mol
Tar_cell_CD19_bm_0 = CD19_per_Tarcell*Rtarcells_bm_number_0 / N_AV * nmol_per_mol
# Surface areas per cell
area_per_Tcell_dm2:(dm^2) = area_per_Tcell_um2 / (um_per_dm^2)
area_per_Bcell_dm2:(dm^2) = area_per_Bcell_um2 / (um_per_dm^2)
area_per_Rtarcell_dm2:(dm^2) = area_per_Rtarcell_um2 / (um_per_dm^2)
\#\#\# In order to incorporate cells, we would need to dynamically account for them
### Defining them here will allow for dynamic incorporation of actual cell number in the necessary
parameters and rates
# Compartments
central~3 = volume_central
peripheral~3 = volume_peripheral
bone_marrow~3 = volume_bone_marrow
# States - initialize to nmol because of default
Rtarcells_c_nmol@central* = Rtarcells_c_number_0 / N_AV * nmol_per_mol
Rtarcells_p_nmol@peripheral* = Rtarcells_p_number_0 / N_AV * nmol_per_mol
Rtarcells_bm_nmol@bone_marrow* = Rtarcells_bm_number_0 / N_AV * nmol_per_mol
Bcells_c_nmol@central* = Bcells_c_number_0 / N_AV * nmol_per_mol
Bcells_p_nmol@peripheral* = Bcells_p_number_0 / N_AV * nmol_per_mol
Bcells_bm_nmol@bone_marrow* = Bcells_bm_number_0 / N_AV * nmol_per_mol
Rtarcells_c_number:1 = Rtarcells_c_nmol / nmol_per_mol * N_AV
Rtarcells_p_number:1 = Rtarcells_p_nmol / nmol_per_mol * N_AV
Rtarcells_bm_number:1 = Rtarcells_bm_nmol / nmol_per_mol * N_AV
Bcells_c_number:1 = Bcells_c_nmol / nmol_per_mol * N_AV
Bcells_p_number:1 = Bcells_p_nmol / nmol_per_mol * N_AV
Bcells_bm_number:1 = Bcells_bm_nmol / nmol_per_mol * N_AV
# Individual cell type surface areas
Tcell_area_c_dm2:(dm^2) = area_per_Tcell_dm2 * Tcells_c_number_0
Tcell_area_p_dm2:(dm^2) = area_per_Tcell_dm2 * Tcells_p_number_0
Tcell_area_bm_dm2:(dm^2) = area_per_Tcell_dm2 * Tcells_bm_number_0
Bcell_area_c_dm2:(dm^2) = area_per_Bcell_dm2 * Bcells_c_number
Bcell_area_p_dm2:(dm^2) = area_per_Bcell_dm2 * Bcells_p_number
Bcell_area_bm_dm2:(dm^2) = area_per_Bcell_dm2 * Bcells_bm_number
Rtarcell_area_c_dm2:(dm^2) = area_per_Rtarcell_dm2 * Rtarcells_c_number
Rtarcell_area_p_dm2:(dm^2) = area_per_Rtarcell_dm2 * Rtarcells_p_number
Rtarcell_area_bm_dm2:(dm^2) = area_per_Rtarcell_dm2 * Rtarcells_bm_number
```

```
# Total cell surface areas
total_normal_cell_area_c:(dm^2) = Tcell_area_c_dm2 + Bcell_area_c_dm2
total_normal_cell_area_p:(dm^2) = Tcell_area_p_dm2 + Bcell_area_p_dm2
total_normal_cell_area_bm:(dm^2) = Tcell_area_bm_dm2 + Bcell_area_bm_dm2
total_cancer_cell_area_c:(dm^2) = Tcell_area_c_dm2 + Rtarcell_area_c_dm2
total_cancer_cell_area_p:(dm^2) = Tcell_area_p_dm2 + Rtarcell_area_p_dm2
total_cancer_cell_area_bm:(dm^2) = Tcell_area_bm_dm2 + Rtarcell_area_bm_dm2
# synthesis rates
ksyn_CD3_c = CD3_c_0 * kint_CD3
ksyn_CD3_p = CD3_p_0 * kint_CD3
ksyn_CD3_bm = CD3_bm_0 * kint_CD3
ksyn_CD19_normal_c = CD19_per_Bcell * Bcells_c_number / N_AV * nmol_per_mol *
kint_CD19
ksyn_CD19_normal_p = CD19_per_Bcell * Bcells_p_number / N_AV * nmol_per_mol *
kint_CD19
ksyn_CD19_normal_bm = CD19_per_Bcell * Bcells_bm_number / N_AV * nmol_per_mol *
kint_CD19
ksyn_CD19_cancer_c = CD19_per_Tarcell * Rtarcells_c_number / N_AV * nmol_per_mol *
kint_CD19
ksyn_CD19_cancer_p = CD19_per_Tarcell * Rtarcells_p_number / N_AV * nmol_per_mol *
kint_CD19
ksyn_CD19_cancer_bm = CD19_per_Tarcell * Rtarcells_bm_number / N_AV * nmol_per_mol *
kint_CD19
```

```
#### Doses ####
IV_nmol: nmol = null; Ab_00_00_c += amt
SC_nmol: nmol = null; Ab_depot += amt * fbio
# This takes a mpk amount and applies it to the free drug or subcutaneous drug. The code converts the
mpk to nmols using rule variables defined earlier in the file.
IV_mpk: (mg/kg) = null; Ab_00_00_c += amt * (nmol_per_mol * BW_kg) / (mg_per_g * mw)
SC_mpk: (mg/kg) = null; Ab_depot += amt * fbio * (nmol_per_mol * BW_kg) / (mg_per_g * mw)
### Infusion ###
amount_infusion_mgperkghr:(mg/(kg*hr)) := 0
duration_infusion_d:d := 28
duration_infusion = duration_infusion_d * SECONDS_PER_DAY
amount_infusion = duration_infusion_d * (24:hr/1:d) * amount_infusion_mgperkghr
# Calculate infusion rate
k_inject: (mg/kg)/s = amount_infusion/duration_infusion # injection rate
start_time:s =0 # Time injection starts
end_time: s = duration_infusion # Time injection ends
```

```
nothing = 1:(1/(mg/kg)) # unbreaks unit checking
dummy_inf *= 0
dummy_inf -> dummy_inf + Ab_00_00_c; kf=k_inject*nothing
IV_inf = ListSchedule(times=[start_time,end_time], amounts=[1:(mg/kg),-1:(mg/kg)]); dummy_inf += amt *
(nmol_per_mol * BW_kg) / (mg_per_g * mw)
#######################################################################################
##
# Compartments
membrane_central~2 = total_normal_cell_area_c
membrane_peripheral~2 = total_normal_cell_area_p
membrane_bone_marrow~2 = total_normal_cell_area_bm
# States
# Central
Ab_depot@central* = 0
Ab_00_00_c@central* = 0
Ab_CD3_00_c@membrane_central* = 0
Ab_00_CD19_normal_c@membrane_central* = 0
Ab_CD3_CD19_normal_c@membrane_central* = 0
Ab_00_CD19_cancer_c@membrane_central* = 0
Ab_CD3_CD19_cancer_c@membrane_central* = 0
CD3_c@membrane_central* = CD3_c_0
CD19_normal_c@membrane_central* = B_cell_CD19_c_0
CD19_cancer_c@membrane_central* = Tar_cell_CD19_c_0
# Peripheral
Ab_00_00_p@peripheral* = 0
Ab_CD3_00_p@membrane_peripheral* = 0
Ab_00_CD19_normal_p@membrane_peripheral* = 0
Ab_CD3_CD19_normal_p@membrane_peripheral* = 0
Ab_00_CD19_cancer_p@membrane_peripheral* = 0
Ab_CD3_CD19_cancer_p@membrane_peripheral* = 0
CD3_p@membrane_peripheral* = CD3_p_0
CD19_normal_p@membrane_peripheral* = B_cell_CD19_p_0
CD19_cancer_p@membrane_peripheral* = Tar_cell_CD19_p_0
# Bone marrow
Ab_00_00_bm@bone_marrow* = 0
Ab_CD3_00_bm@membrane_bone_marrow* = 0
```

```
Ab_00_CD19_normal_bm@membrane_bone_marrow* = 0
Ab_CD3_CD19_normal_bm@membrane_bone_marrow* = 0
Ab_00_CD19_cancer_bm@membrane_bone_marrow* = 0
Ab_CD3_CD19_cancer_bm@membrane_bone_marrow* = 0
CD3_bm@membrane_bone_marrow* = CD3_bm_0
CD19_normal_bm@membrane_bone_marrow* = B_cell_CD19_bm_0
CD19_cancer_bm@membrane_bone_marrow* = Tar_cell_CD19_bm_0
#### Reactions #################################
### Synthesis and degradation reactions
# Central
Ab_depot -> Ab_00_00_c; kf = kabs
    <-> CD3_c; kf = ksyn_CD3_c, kr = kint_CD3
    <-> CD19_normal_c; kf = ksyn_CD19_normal_c, kr = kint_CD19
    <-> CD19_cancer_c; kf = ksyn_CD19_cancer_c, kr = kint_CD19
# Drug degradation reactions
Ab_00_00_c ->; kf = kel_Ab
Ab_CD3_00_c ->; kf = kint_Ab_CD3
Ab_00_CD19_normal_c ->; kf = kint_Ab_CD19
Ab_00_CD19_cancer_c ->; kf = kint_Ab_CD19
# internalization of trimer returns a receptor - keep receptor number constant
Ab_CD3_CD19_normal_c -> CD3_c; kf = kint_Ab_CD19
Ab_CD3_CD19_normal_c -> CD19_normal_c; kf = kint_Ab_CD3
Ab_CD3_CD19_cancer_c -> CD3_c; kf = kint_Ab_CD19
Ab_CD3_CD19_cancer_c -> CD19_cancer_c; kf = kint_Ab_CD3
# Peripheral
    <-> CD3_p; kf = ksyn_CD3_p, kr = kint_CD3
    <-> CD19_normal_p; kf = ksyn_CD19_normal_p, kr = kint_CD19
    <-> CD19_cancer_p; kf = ksyn_CD19_cancer_p, kr = kint_CD19
# Drug degradation reactions
Ab_00_00_p ->; }\quadkf=kel_A
Ab_CD3_00_p ->; kf = kint_Ab_CD3
Ab_00_CD19_normal_p ->; kf = kint_Ab_CD19
Ab_00_CD19_cancer_p ->; kf = kint_Ab_CD19
# internalization of trimer returns a receptor - keep receptor number constant
Ab_CD3_CD19_normal_p -> CD3_p; kf = kint_Ab_CD19
Ab_CD3_CD19_normal_p -> CD19_normal_p; kf = kint_Ab_CD3
Ab_CD3_CD19_cancer_p -> CD3_p; kf = kint_Ab_CD19
Ab_CD3_CD19_cancer_p -> CD19_cancer_p; kf = kint_Ab_CD3
# Bone marrow
    <-> CD3_bm; kf = ksyn_CD3_bm, kr = kint_CD3
```

```
<-> CD19_normal_bm; \(\quad \mathrm{kf}=\mathrm{ksyn}\) _CD19_normal_bm, \(k r=k i n t \_C D 19\)
<-> CD19_cancer_bm; \(k f=k s y n \_C D 19 \_c a n c e r \_b m, ~ k r ~=~ k i n t \_C D 19 ~\)
\# Drug degradation reactions
Ab_00_00_bm ->; \(\quad k f=k e l \_A b\)
Ab_CD3_00_bm ->; \(\quad k f=k i n t \_A b \_C D 3\)
Ab_00_CD19_normal_bm ->; \(k f=k i n t \_A b \_C D 19\)
Ab_00_CD19_cancer_bm ->; kf = kint_Ab_CD19
\# internalization of trimer returns a receptor - keep receptor number constant
Ab_CD3_CD19_normal_bm \(\quad \rightarrow\) CD3_bm; \(\quad k f=k i n t \_A b \_C D 19\)
Ab_CD3_CD19_normal_bm -> CD19_normal_bm; \(\quad \mathrm{kf}=\mathrm{kint}\) _Ab_CD3
Ab_CD3_CD19_cancer_bm -> CD3_bm; \(k f=k i n t \_A b \_C D 19\)
Ab_CD3_CD19_cancer_bm -> CD19_cancer_bm; \(k f=k i n t \_A b \_C D 3\)
\# Distribution
Ab_00_00_c \(<->\) Ab_00_00_p; kf \(=k 12, k r=k 21\)
Ab_00_00_c <-> Ab_00_00_bm; \(k f=k 13, k r=k 31\)
\#\#\# Binding \#\#\#
\# Central
Ab_00_00_c + CD3_c <-> Ab_CD3_00_c; \(k f=k o n \_A b \_C D 3, k r=k o f f \_A b \_C D 3\)
Ab_00_00_c + CD19_normal_c <-> Ab_00_CD19_normal_c; \(k f=k o n \_A b \_C D 19, k r=k o f f \_A b \_C D 19\)
Ab_CD3_00_c + CD19_normal_c <-> Ab_CD3_CD19_normal_c; \(k f=k o n 2 \_A b \_C D 19, k r=\)
koff_Ab_CD19
Ab_00_CD19_normal_c + CD3_c <-> Ab_CD3_CD19_normal_c; \(k f=k o n 2 \_A b \_C D 3, k r=k o f f \_A b \_C D 3\)
Ab_00_00_c + CD19_cancer_c <-> Ab_00_CD19_cancer_c; \(k f=k o n \_A b \_C D 19, k r=k o f f \_A b \_C D 19\)
\# adjust second reaction for the different surface areas
Ab_CD3_00_c + CD19_cancer_c <-> Ab_CD3_CD19_cancer_c; \(k f=\)
kon2_Ab_CD19*total_normal_cell_area_c/total_cancer_cell_area_c, \(\mathrm{kr}=\mathrm{koff}\) _Ab_CD19
Ab_00_CD19_cancer_c + CD3_c <-> Ab_CD3_CD19_cancer_c; \(k f=\)
kon2_Ab_CD3*total_normal_cell_area_c/total_cancer_cell_area_c, kr = koff_Ab_CD3
\# Peripheral
Ab_00_00_p + CD3_p <-> Ab_CD3_00_p; kf = kon_Ab_CD3, kr = koff_Ab_CD3
Ab_00_00_p + CD19_normal_p <-> Ab_00_CD19_normal_p; \(k f=k o n \_A b \_C D 19, k r=k o f f \_A b \_C D 19\)
Ab_CD3_00_p + CD19_normal_p <-> Ab_CD3_CD19_normal_p; \(k f=k o n 2 \_A b \_C D 19, k r=\)
koff_Ab_CD19
Ab_00_CD19_normal_p + CD3_p <-> Ab_CD3_CD19_normal_p; \(k f=k o n 2 \_A b \_C D 3, k r=k o f f \_A b \_C D 3\)
Ab_00_00_p + CD19_cancer_p <-> Ab_00_CD19_cancer_p; \(k f=k o n \_A b \_C D 19, k r=k o f f \_A b \_C D 19\)
\# adjust second reaction for the different surface areas
Ab_CD3_00_p + CD19_cancer_p <-> Ab_CD3_CD19_cancer_p; kf =
kon2_Ab_CD19*total_normal_cell_area_p/total_cancer_cell_area_p, kr = koff_Ab_CD19
Ab_00_CD19_cancer_p + CD3_p <-> Ab_CD3_CD19_cancer_p; kf =
kon2_Ab_CD3*total_normal_cell_area_p/total_cancer_cell_area_p, \(k r=k o f f \_A b \_C D 3\)
\# Bone marrow
```

```
Ab_00_00_bm + CD3_bm <-> Ab_CD3_00_bm; kf = kon_Ab_CD3, kr = koff_Ab_CD3
Ab_00_00_bm + CD19_normal_bm <-> Ab_00_CD19_normal_bm; kf = kon_Ab_CD19, kr =
koff_Ab_CD19
Ab_CD3_00_bm + CD19_normal_bm <-> Ab_CD3_CD19_normal_bm; kf = kon2_Ab_CD19, kr =
koff_Ab_CD19
Ab_00_CD19_normal_bm + CD3_bm <-> Ab_CD3_CD19_normal_bm; kf = kon2_Ab_CD3, kr =
koff_Ab_CD3
Ab_00_00_bm + CD19_cancer_bm <-> Ab_00_CD19_cancer_bm; kf = kon_Ab_CD19, kr =
koff_Ab_CD19
# adjust second reaction for the different surface areas
Ab_CD3_00_bm + CD19_cancer_bm <-> Ab_CD3_CD19_cancer_bm; kf =
kon2_Ab_CD19*total_normal_cell_area_bm/total_cancer_cell_area_bm, kr = koff_Ab_CD19
Ab_00_CD19_cancer_bm + CD3_bm <-> Ab_CD3_CD19_cancer_bm; kf =
kon2_Ab_CD3*total_normal_cell_area_bm/total_cancer_cell_area_bm, kr = koff_Ab_CD3
#### Defining model readouts ####
## Main outputs
# PK
free_Ab_central_nM = Ab_00_00_c / volume_central
free_Ab_central_ugml = free_Ab_central_nM * ugml_per_nM
pk_pg_ml = free_Ab_central_ugml * 1e6
# AUC
AUC@central:(nmol*s)* = 0
-> AUC; kf = Ab_00_00_c
AUC_ugmlh:(ug/mL * hr) = AUC / volume_central * ugml_per_nM / SECONDS_PER_HOUR
AUC_ugmld:(ug/mL * d) = AUC_ugmlh / 24:(hr/d)
# Cav
Cav_nM:(nmol/L) = AUC / t / volume_central
Cav_ugml:(ug/mL) = Cav_nM * ugml_per_nM
# Trimer
total_trimer_normal_central = Ab_CD3_CD19_normal_c
total_trimer_normal_peripheral = Ab_CD3_CD19_normal_p
total_trimer_normal_bone_marrow = Ab_CD3_CD19_normal_bm
total_trimer_cancer_central = Ab_CD3_CD19_cancer_c
total_trimer_cancer_peripheral = Ab_CD3_CD19_cancer_p
total_trimer_cancer_bone_marrow = Ab_CD3_CD19_cancer_bm
trimer_per_Tcell_normal_central:1 = Ab_CD3_CD19_normal_c * NUM_PER_NMOL /
Tcells_c_number_0
trimer_per_Bcell_normal_central:1 = Ab_CD3_CD19_normal_c * NUM_PER_NMOL /
(Bcells_c_number + 1e-16:1)
trimer_per_Tcell_cancer_central:1 = Ab_CD3_CD19_cancer_c * NUM_PER_NMOL /
Tcells_c_number_0
```

```
trimer_per_cancer_cell_central:1 = Ab_CD3_CD19_cancer_c * NUM_PER_NMOL /
(Rtarcells_c_number + 1e-16:1)
trimer_per_Tcell_normal_peripheral:1 = Ab_CD3_CD19_normal_p * NUM_PER_NMOL /
Tcells_p_number_0
trimer_per_Bcell_normal_peripheral:1 = Ab_CD3_CD19_normal_p * NUM_PER_NMOL /
(Bcells_p_number + 1e-16:1)
trimer_per_Tcell_cancer_peripheral:1 = Ab_CD3_CD19_cancer_p * NUM_PER_NMOL /
Tcells_p_number_0
trimer_per_cancer_cell_peripheral:1 = Ab_CD3_CD19_cancer_p * NUM_PER_NMOL /
(Rtarcells_p_number + 1e-16:1)
trimer_per_Tcell_normal_bone_marrow:1 = Ab_CD3_CD19_normal_bm * NUM_PER_NMOL /
Tcells_bm_number_0
trimer_per_Bcell_normal_bone_marrow:1 = Ab_CD3_CD19_normal_bm * NUM_PER_NMOL /
(Bcells_bm_number + 1e-16:1)
trimer_per_Tcell_cancer_bone_marrow:1 = Ab_CD3_CD19_cancer_bm * NUM_PER_NMOL /
Tcells_bm_number_0
trimer_per_cancer_cell_bone_marrow:1 = Ab_CD3_CD19_cancer_bm * NUM_PER_NMOL /
(Rtarcells_bm_number + 1e-16:1)
# Avg Trimer
total_trimer_auc_normal_central@central:(nmol*s)* = 0
total_trimer_auc_normal_peripheral@peripheral:(nmol*s)* = 0
total_trimer_auc_normal_bone_marrow@bone_marrow:(nmol*s)* = 0
-> total_trimer_auc_normal_central; kf = total_trimer_normal_central
-> total_trimer_auc_normal_peripheral; kf = total_trimer_normal_peripheral
-> total_trimer_auc_normal_bone_marrow; kf = total_trimer_normal_bone_marrow
total_trimer_auc_cancer_central@central:(nmol*s)* = 0
total_trimer_auc_cancer_peripheral@peripheral:(nmol*s)* = 0
total_trimer_auc_cancer_bone_marrow@bone_marrow:(nmol*s)* = 0
-> total_trimer_auc_cancer_central; kf = total_trimer_cancer_central
-> total_trimer_auc_cancer_peripheral; kf = total_trimer_cancer_peripheral
-> total_trimer_auc_cancer_bone_marrow; kf = total_trimer_cancer_bone_marrow
trimer_per_Tcell_auc_normal_central:s = total_trimer_auc_normal_central * NUM_PER_NMOL /
Tcells_c_number_0
trimer_per_Bcell_auc_normal_central:s = total_trimer_auc_normal_central * NUM_PER_NMOL /
(Bcells_c_number + 1e-16:1)#Bcells_c_number_0
trimer_per_Tcell_auc_cancer_central:s = total_trimer_auc_cancer_central * NUM_PER_NMOL /
Tcells_c_number_0
trimer_per_cancer_cell_auc_central:s = total_trimer_auc_cancer_central * NUM_PER_NMOL /
(Rtarcells_c_number + 1e-16:1)#Rtarcells_c_number_0
trimer_per_Tcell_auc_normal_peripheral:s = total_trimer_auc_normal_peripheral * NUM_PER_NMOL /
Tcells_p_number_0
```

```
trimer_per_Bcell_auc_normal_peripheral:s = total_trimer_auc_normal_peripheral * NUM_PER_NMOL /
(Bcells_p_number + 1e-16:1)#Bcells_p_number_0
trimer_per_Tcell_auc_cancer_peripheral:s = total_trimer_auc_cancer_peripheral * NUM_PER_NMOL /
Tcells_p_number_0
trimer_per_cancer_cell_auc_peripheral:s = total_trimer_auc_cancer_peripheral * NUM_PER_NMOL /
(Rtarcells_p_number + 1e-16:1)#Rtarcells_p_number_0
trimer_per_Tcell_auc_normal_bone_marrow:s = total_trimer_auc_normal_bone_marrow *
NUM_PER_NMOL / Tcells_bm_number_0
trimer_per_Bcell_auc_normal_bone_marrow:s = total_trimer_auc_normal_bone_marrow *
NUM_PER_NMOL / (Bcells_bm_number + 1e-16:1)#Bcells_bm_number_0
trimer_per_Tcell_auc_cancer_bone_marrow:s = total_trimer_auc_cancer_bone_marrow *
NUM_PER_NMOL / Tcells_bm_number_0
trimer_per_cancer_cell_auc_bone_marrow:s = total_trimer_auc_cancer_bone_marrow *
NUM_PER_NMOL / (Rtarcells_bm_number + 1e-16:1)#Rtarcells_bm_number_0
avg_trimer_per_Tcell_normal_central:1 = trimer_per_Tcell_auc_normal_central / (t + 1e-6:s)
avg_trimer_per_Tcell_normal_peripheral:1 = trimer_per_Tcell_auc_normal_peripheral / (t + 1e-6:s)
avg_trimer_per_Tcell_normal_bone_marrow:1 = trimer_per_Tcell_auc_normal_bone_marrow / (t + 1e-
6:s)
avg_trimer_per_Bcell_normal_central:1 = trimer_per_Bcell_auc_normal_central / (t + 1e-6:s)
avg_trimer_per_Bcell_normal_peripheral:1 = trimer_per_Bcell_auc_normal_peripheral / ( t + 1e-6:s)
avg_trimer_per_Bcell_normal_bone_marrow:1 = trimer_per_Bcell_auc_normal_bone_marrow / (t + 1e-
6:s)
avg_trimer_per_Tcell_cancer_central:1 = trimer_per_Tcell_auc_cancer_central / ( t + 1e-6:s)
avg_trimer_per_Tcell_cancer_peripheral:1 = trimer_per_Tcell_auc_cancer_peripheral / (t + 1e-6:s)
avg_trimer_per_Tcell_cancer_bone_marrow:1 = trimer_per_Tcell_auc_cancer_bone_marrow / (t + 1e-
6:s)
avg_trimer_per_cancer_cell_central:1 = trimer_per_cancer_cell_auc_central / (t+1e-6:s)
avg_trimer_per_cancer_cell_peripheral:1 = trimer_per_cancer_cell_auc_peripheral / (t + 1e-6:s)
avg_trimer_per_cancer_cell_bone_marrow:1 = trimer_per_cancer_cell_auc_bone_marrow / (t + 1e-6:s)
# RO
RO_CD3_central = (Ab_CD3_00_c + Ab_CD3_CD19_normal_c + Ab_CD3_CD19_cancer_c) / (CD3_c +
Ab_CD3_00_c + Ab_CD3_CD19_normal_c + Ab_CD3_CD19_cancer_c + 1e-15:nmol) * 100
RO_CD3_peripheral = (Ab_CD3_00_p + Ab_CD3_CD19_normal_p + Ab_CD3_CD19_cancer_p) /
(CD3_p + Ab_CD3_00_p + Ab_CD3_CD19_normal_p + Ab_CD3_CD19_cancer_p + 1e-15:nmol) * 100
RO_CD3_bone_marrow = (Ab_CD3_00_bm + Ab_CD3_CD19_normal_bm +
Ab_CD3_CD19_cancer_bm) / (CD3_bm + Ab_CD3_00_bm + Ab_CD3_CD19_normal_bm +
Ab_CD3_CD19_cancer_bm + 1e-15:nmol) * 100
RO_CD19_normal_central = (Ab_00_CD19_normal_c + Ab_CD3_CD19_normal_c) / (CD19_normal_c +
Ab_00_CD19_normal_c + Ab_CD3_CD19_normal_c + 1e-15:nmol) * 100
RO_CD19_normal_peripheral = (Ab_00_CD19_normal_p + Ab_CD3_CD19_normal_p) /
(CD19_normal_p + Ab_00_CD19_normal_p + Ab_CD3_CD19_normal_p + 1e-15:nmol) * 100
```

```
RO_CD19_normal_bone_marrow = (Ab_00_CD19_normal_bm + Ab_CD3_CD19_normal_bm) /
(CD19_normal_bm + Ab_00_CD19_normal_bm + Ab_CD3_CD19_normal_bm + 1e-15:nmol) * 100
RO_CD19_cancer_central = (Ab_00_CD19_cancer_c + Ab_CD3_CD19_cancer_c) / (CD19_cancer_c +
Ab_00_CD19_cancer_c + Ab_CD3_CD19_cancer_c + 1e-15:nmol) * 100
RO_CD19_cancer_peripheral = (Ab_00_CD19_cancer_p + Ab_CD3_CD19_cancer_p) / (CD19_cancer_p
+ Ab_00_CD19_cancer_p + Ab_CD3_CD19_cancer_p + 1e-15:nmol) * 100
RO_CD19_cancer_bone_marrow = (Ab_00_CD19_cancer_bm + Ab_CD3_CD19_cancer_bm) /
(CD19_cancer_bm + Ab_00_CD19_cancer_bm + Ab_CD3_CD19_cancer_bm + 1e-15:nmol) * 100
# Avg RO
RO_CD3_auc_central@central:s* = 0
RO_CD19_auc_normal_central@central:s* = 0
RO_CD19_auc_cancer_central@central:s* = 0
RO_CD3_auc_peripheral@peripheral:s* = 0
RO_CD19_auc_normal_peripheral@peripheral:s* = 0
RO_CD19_auc_cancer_peripheral@peripheral:s* = 0
RO_CD3_auc_bone_marrow@bone_marrow:s* = 0
RO_CD19_auc_normal_bone_marrow@bone_marrow:s* = 0
RO_CD19_auc_cancer_bone_marrow@bone_marrow:s* = 0
-> RO_CD3_auc_central; kf = RO_CD3_central
-> RO_CD19_auc_normal_central; kf = RO_CD19_normal_central
-> RO_CD19_auc_cancer_central; kf = RO_CD19_cancer_central
-> RO_CD3_auc_peripheral; kf = RO_CD3_peripheral
-> RO_CD19_auc_normal_peripheral; kf = RO_CD19_normal_peripheral
-> RO_CD19_auc_cancer_peripheral; kf = RO_CD19_cancer_peripheral
-> RO_CD3_auc_bone_marrow; kf = RO_CD3_bone_marrow
-> RO_CD19_auc_normal_bone_marrow; kf = RO_CD19_normal_bone_marrow
-> RO_CD19_auc_cancer_bone_marrow; kf = RO_CD19_cancer_bone_marrow
Avg_RO_CD3_central = RO_CD3_auc_central/t
Avg_RO_CD19_normal_central = RO_CD19_auc_normal_central/t
Avg_RO_CD19_cancer_central = RO_CD19_auc_cancer_central/t
Avg_RO_CD3_peripheral = RO_CD3_auc_peripheral/t
Avg_RO_CD19_normal_peripheral = RO_CD19_auc_normal_peripheral/t
Avg_RO_CD19_cancer_peripheral = RO_CD19_auc_cancer_peripheral/t
Avg_RO_CD3_bone_marrow = RO_CD3_auc_bone_marrow/t
Avg_RO_CD19_normal_bone_marrow = RO_CD19_auc_normal_bone_marrow/t
Avg_RO_CD19_cancer_bone_marrow = RO_CD19_auc_cancer_bone_marrow/t
## Auxiliary outputs
free_Ab_peripheral_nM = Ab_00_00_p/volume_peripheral
free_Ab_bone_marrow_nM = Ab_00_00_bm/volume_bone_marrow
total_drug_central = Ab_00_00_c + Ab_CD3_00_c + Ab_00_CD19_normal_c +
Ab_CD3_CD19_normal_c + Ab_00_CD19_cancer_c + Ab_CD3_CD19_cancer_c
total_CD19_central = CD19_normal_c + CD19_cancer_c + Ab_00_CD19_normal_c +
Ab_CD3_CD19_normal_c + Ab_00_CD19_cancer_c + Ab_CD3_CD19_cancer_c
```

```
free_CD3_central = CD3_c
free_CD19_normal_central = CD19_normal_c
free_CD19_cancer_central = CD19_cancer_c
free_CD3_peripheral = CD3_p
free_CD19_normal_peripheral = CD19_normal_p
free_CD19_cancer_peripheral = CD19_cancer_p
free_CD3_bone_marrow = CD3_bm
free_CD19_normal_bone_marrow = CD19_normal_bm
free_CD19_cancer_bone_marrow = CD19_cancer_bm
### Cell killing
f_kill_central:(1/s) = k_kill*avg_trimer_per_Tcell_normal_central/(kill_EC50 +
avg_trimer_per_Tcell_normal_central)
f_kill_peripheral:(1/s) = k_kill*avg_trimer_per_Tcell_normal_peripheral/(kill_EC50 +
avg_trimer_per_Tcell_normal_peripheral)
f_kill_bone_marrow:(1/s) = k_kill*avg_trimer_per_Tcell_normal_bone_marrow/(kill_EC50 +
avg_trimer_per_Tcell_normal_bone_marrow)
Bcells_c_nmol ->; kf = f_kill_central
Bcells_p_nmol ->; kf = f_kill_peripheral
Bcells_bm_nmol ->; kf = f_kill_bone_marrow
# everything that's on the dead cell also ought to disappear
Ab_00_CD19_normal_c ->; kf = f_kill_central
Ab_CD3_CD19_normal_c ->; kf = f_kill_central
CD19_normal_c ->; kf = f_kill_central
Ab_00_CD19_normal_p ->; kf = f_kill_peripheral
Ab_CD3_CD19_normal_p ->; kf = f_kill_peripheral
CD19_normal_p ->; kf = f_kill_peripheral
Ab_00_CD19_normal_bm ->; kf = f_kill_bone_marrow
Ab_CD3_CD19_normal_bm ->; kf = f_kill_bone_marrow
CD19_normal_bm ->; kf = f_kill_bone_marrow
```

